CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | pCODR 10111 |
|---|---|
| Brand Name | Lartruvo |
| Generic Name | Olaratumab |
| Strength | 10 mg/mL |
| Tumour Type | Sarcoma |
| Indication | Advanced Soft Tissue Sarcoma (STS) |
| Funding Request | In combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and for whom treatment with an anthracycline-containing regimen is appropriate |
| Review Status | Notification to Implement Issued |
| Pre Noc Submission | Yes |
| NOC Date | November 23, 2017 |
| Manufacturer | Eli Lilly Canada Inc. |
| Sponsor | Eli Lilly Canada Inc. |
| Submission Date | October 26, 2017 |
| Submission Deemed Complete | November 2, 2017 |
| Submission Type | New Indication |
| Prioritization Requested | Requested and Granted |
| Stakeholder Input Deadline ‡ | November 9, 2017 |
| Check-point meeting | December 13, 2017 |
| pERC Meeting | March 15, 2018 |
| Initial Recommendation Issued | March 29, 2018 |
| Feedback Deadline ‡ | April 13, 2018 |
| Final Recommendation Issued | April 18, 2018 |
| Notification to Implement Issued | May 3, 2018 |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
